A synthetic analogue of glucagon-like peptide-1, an incretin peptide released from the gut. It is modified to resist enzymatic breakdown and to bind albumin reversibly.

Why is the native peptide difficult to study?

Native GLP-1 is cleaved by the enzyme DPP-4 within minutes of release, giving it a very short window. The analogue's substitutions block that cleavage.

What does the fatty-acid chain do?

It promotes reversible binding to albumin in circulation, which slows clearance and extends the time the molecule remains available in preclinical models.

20 mg of lyophilised powder in a sealed crimp-top vial, assayed at ≥99% purity by HPLC-UV with identity confirmed by LC-MS.

Is a certificate of analysis available?

Yes. A batch-level certificate is issued against the lot number and covers the material you receive.

GLP-1 (S)

Acylated GLP-1 receptor agonist studied for extended circulation

99.36% pure on this exact lot, verified by an independent lab, not by us
Tested in America. Ships within 1 business day, stored frozen, stable at room temperature until you mix it
Retest it at any lab. If it doesn't match our report, every dollar back

$89/ 20mg vial

$44.50 per vial with Buy 1, Get 1 Free

Buy 1, Get 1 Free — add 2 to cart, applied automatically

In stock

99.36% pure on this exact lot, verified by an independent lab, not by us
Tested in America. Ships within 1 business day, stored frozen, stable at room temperature until you mix it
Retest it at any lab. If it doesn't match our report, every dollar back

VISAAMEXPayPal

Secure checkout

All products currently listed on this site are for research purposes only.

Frequently bought together

Related laboratory supplies.

Reconstitution Solution · 3ml

Essential

GHK-Cu · 50mg

Melanotan II · 10mg

Add all (3)$97

Certificate of analysis

Every vial ships with its own report

We don't publish a brand-wide spec sheet and call it a “COA.” The certificate you receive references the actual lot number stamped on your vial — with the raw chromatograms attached.

Lot-specific HPLC purity + LC-MS identity
Raw chromatogram + mass confirmation attached
Signed off by the lab's Principal Chemist
Permanent archive — searchable by lot ID

or browse the lot archive

GLP-1 (S) · 20mgLot D15SS7Live

Purity by HPLC-UV

99.36%

Tested by: ILS Laboratories
Tested on: 30 Oct 2026
Net content: 21.03 mg

Contaminant screens

Heavy metalsEndotoxinsMicrobialSolvents

See all lab reports

Live batch data

ILS Laboratories

Independent analytical lab

Certificate of Analysis

RESULT · PASS

Lot D15SS7Verified

GLP-1 (S) 20mg

HPLC purity

99.36%

Pass · Meets spec

Tested

30 Oct 2026

HPLC-UV + LC-MS

Analytical results

Identity (LC-MS)ConfirmedPASS

Net content21.03 mgPASS

HPLC Chromatogram

Main peak 99.36% · other 0.64%

Alex JohnsonPrincipal Chemist

Authentichain · Verified 2×

GLP-1 receptorreceptor binding

DPP-4 resistancestability

Albumin bindingcirculation

How GLP-1 (S) works

Researchers study GLP-1 (S) as acting through three broad routes.

GLP-1 receptorreceptor binding

It is studied as an agonist at the GLP-1 receptor, a class-B G-protein-coupled receptor.

DPP-4 resistancestability

Substitution at the cleavage site is studied for resisting the enzyme that clears the native peptide.

Albumin bindingcirculation

The acyl chain is studied for reversible albumin association, extending time in circulation.

For research use only. Mechanisms described reflect published preclinical literature.

Every batch we've tested

Anyone can show you one good report. Here is every batch of GLP-1 (S) we have ever released, newest first, each with its own signed report. Nothing hidden, nothing cherry-picked.

3 batches on record · latest tested 30 Oct 2026

All lab reportsEvery GLP-1 (S) batch, on one page.The full testing history with every signed report. No login, no email wall.See all lab reports

What the studies found

Published findings on this compound, each linked to its source. Animal and lab results are context, not claims about this product.

Body weightClinical

−14.9%

In a 68-week trial of 1,961 adults with obesity or overweight, those on semaglutide lost an average of 14.9% of their body weight.

vs −2.4% on placebo

NEJM 2021 · STEP 1 RCT, n=1,961

Placebo−2.4%

Semaglutide−14.9%

Mean change in body weight at 68 weeks

Heart eventsClinical

−20%

In 17,604 adults with heart or artery disease and overweight but no diabetes, those on semaglutide had a 20% lower risk of heart attack, stroke or heart death over 39.8 months.

6.5% vs 8.0% on placebo

Placebo8.0%

Semaglutide6.5%

Share with heart attack, stroke or heart death

NEJM 2023 · SELECT RCT, n=17,604

Kidney healthClinical

−24%

In 3,533 adults with type 2 diabetes and kidney disease, semaglutide cut the risk of kidney failure, steep kidney decline or kidney or heart death by 24%.

331 vs 410 events on placebo

Main kidney outcome0.76

Heart death0.71

Death from any cause0.80

No effect

Hazard ratio vs placebo, median 3.4 years

NEJM 2024 · FLOW RCT, n=3,533